CAS: 683-10-3; (Lauryldimethylammonio)Acetate

相似化合物

7009-61-2 4292-10-8 10534-59-5

上下游产品

CAS号112-18-5 十二烷基二甲基叔胺 | CAS号79-11-8 氯乙酸 | CAS号3926-62-3 氯乙酸钠 | CAS号143-15-7 溴代十二烷 | CAS号17283-72-6 methyl N-dodecy... | CAS号77814-51-8 methyl N-dodecy... | CAS号105-39-5 氯乙酸乙酯

乙二醇单十二烷基醚置于吡啶,三溴化磷,Sodium Hydroxide体系中,用 水,苯 作为反应溶剂,-10.0~95.0 °C,101.33 Kpa 条件下,反应 23.0H,反应生成 十二烷基二甲基胺乙内酯
参考文献:一些无环季铵化合物的合成.仲胺和叔胺在两相体系中的烷基化
标题:一些无环季铵化合物的合成.仲胺和叔胺在两相体系中的烷基化
摘要:通式r1R2R3N+ar4Cl-(r1 = Me,Bu; R2 = N-C12H25,Phch2,Cnh2N+1(och2Ch2)M,N = 9 And 12,M = 1)的一系列无环对称和不对称季铵氯化物和 2; R3 = N-C12H25,Phch2,Hoch2Ch2,-oocch2; R4 = N-C12H25,Phch2; A = (Ch2Ch2O)1,2,Ch2C(O)O) 是通过叔胺的烷基化合成的相系统含水.一种合成通式 Menr1R2 的初始对称和不对称叔胺的简便方法(r1 = Me,Bu;r2 = N-C12H25,Phch2,Cnh2N+1(och2Ch2)M,N = 9 和 12,M = 1 和 2) 在有机相-水相非均相系统中被开发出来,它允许使用碱和胺的水溶液.
DOI:10.1007/s11172-014-0761-X

专利信息

专利号:US-8691979-B2
优先权日:2009-05-12
标题 :Methods of chemical synthesis of diaminophenothiazinium compounds involving the use of persulfate oxidants
发明人：LARCH CHRISTOPHER PAUL; STOREY JOHN MERVYN DAVID; WILLIAMSON CRAIG; MARSHALL COLIN; KEMP STEVEN JOHN
权利人:LARCH CHRISTOPHER PAUL; STOREY JOHN MERVYN DAVID; WILLIAMSON CRAIG; MARSHALL COLIN; KEMP STEVEN JOHN; WISTA LAB LTD
摘要:Described are methods of synthesizing and purifying certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compoundsâ€?) including Methylhioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: a thiosulfonic acid formation (TSAF); an oxidative coupling (OC); and a ring closure (RC). Also described are resulting compounds and compositions comprising them (e.g., tablets, capsules) for use in methods of medical treatment and diagnosis, etc., for example, for tauopathies, or Alzheimer's disease (AD).

专利号:US-2011031430-A1
优先权日:2009-08-07
标 题 :Synthesis of water-soluble organic nanoparticles as epr standard
发明人：CAO Y CHARLES; CHEN OU; ANGERHOFER ALEXANDER
权利人:UNIV FLORIDA
摘要:Novel water soluble paramagnetic organic nanoparticles are formed by a novel method where an organic solution of an organic compound is injected into water under agitation that is maintained for a desired period of time for nanoparticle growth followed by termination of the growth by the addition of an aqueous surfactant solution. The size of the nanoparticles depends on the time between injection and addition of the surfactant solution. In embodiments of the invention, the water soluble paramagnetic organic nanoparticles can be DPPH nanoparticles, DPPH nanoparticles doped with DPPH-H, or core/shell nanoparticles where a DPPH core is covered by a DPPH-H shell.

专利号:US-11850220-B2
优先权日:2020-05-19
标题 :Synthesis of ibuprofen hybrid conjugates as anti-inflammatory and analgesic agents
发明人：PANDA SIVA
权利人:UNIV RES INST INC AUGUSTA
摘要:Disclosed herein as ibuprofen hybrid conjugates and methods of their use to reduce inflammation, pain, and fever. The ibuprofen conjugates have potent anti-inflammatory and analgesic properties with low potential for ulcerogenic activity. An exemplary compound is an ibuprofen-amino acid-4-aminophenol hybrid. Also disclosed are methods of treating or reducing inflammation, pain, and fever in a subject.

专利号:US-6599972-B2
优先权日:1996-12-24
标 题 :Latex compositions containing ethylenically unsaturated esters of fatty compounds and applications thereof
发明人：THAMES SHELBY FRELAND; PANJNANI KAMLESH GOPICHAND; FRUCHEY OLAN STANLEY
权利人:UNIV SOUTHERN MISSISSIPPI
摘要:Novel latex or emulsion compositions containing internally plasticizing and crosslinkable monomers derived from traditional semi-drying or non-drying oils are disclosed and claimed. The monomers are ethylenically unsaturated derivatives of long-chain olefinic compounds. Preferred embodiments include latex formed from acrylate or methacrylate esters of fatty alcohols. A process for the synthesis of the latex composition is also disclosed, which involves (a) polymerization of the ethylenically unsaturated derivatives of a long-chain olefinic compound in an aqueous phase with at least one other copolymerizable monomer; and (b) blending of so formed polymer with at least one drier and a surfactant to form the novel latex or emulsion compositions. These compositions form films at low minimum film forming temperatures (MFT) ranging from -5 to 10° C. and cure to above ambient glass transition (Tg) polymers without the use of traditional organic cosolvents which contribute to environmental pollution via volatile organic compounds (VOCs) emissions. These compositions are therefore useful in waterborne coatings, contact and pressure sensitive adhesives, and inks.

专利号:US-9567430-B2
优先权日:2011-12-02
标 题 :Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
发明人：SALTZMAN W MARK; JIANG ZHAOZHONG; ZHOU JIANGBING; LIU JIE
权利人:UNIV YALE
摘要:Poly(amine-co-ester) polymers, methods of forming active agent-load nanoparticles therefrom, and methods of using the nanoparticles for drug delivery are disclosed. The nanoparticles can be coated with an agent that reduces surface charge, an agent that increases cell-specific targeting, or a combination thereof. Typically, the loaded nanoparticles are less toxic, more efficient at drug delivery, or a combination thereof compared to a control other transfection reagents. In some embodiments, the nanoparticles are suitable for in vivo delivery, and can be administered systemically to a subject to treat a disease or condition.

专利号:WO-2013082529-A1
优先权日:2011-12-02
标题 :Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
发明人：SALTZMAN W MARK; JIANG ZHAOZHONG; ZHOU JIANGBING
权利人:UNIV YALE
摘要:Poly(amine-co-ester) polymers, methods of forming active agent-load nanoparticies therefrom, and methods of using the nanoparticies for drug delivery are disclosed. The nanoparticies can be coated with an agent that reduces surface charge, an agent that increases cell-specific targeting, or a combination thereof. Typically, the loaded nanoparticies are less toxic, more efficient at drug delivery, or a combination thereof compared to a control other transfection reagents. In some embodiments, the nanoparticies are suitable for in vivo delivery, and can be administered systemically to a subject to treat a disease or condition.